Jefferies, Morgan Stanley Bullish on Navin Fluorine Amid ₹2,000 Cr Capex Boost

Jefferies’ bullish stance on Navin Fluorine hinges primarily on the successful monetization of its ₹2,000 crore capital expenditure, invested over the last three years in scaling advanced chemical manufacturing capabilities. According to Jefferies, the company is poised to translate this spending into revenue via long-term contracts, particularly in the contract development and manufacturing organization (CDMO) and specialty chemical verticals. The brokerage expects this asset deployment to boost asset turnover and forecasts a sharp 35 percent compound annual growth rate (CAGR) in earnings per share (EPS) from FY25 through FY27. The planned monetization is likely to be driven by global demand for high-purity fluorinated compounds and continued client interest in customized, multi-year supply agreements.

Highlights

• Jefferies sets target price of ₹5,280, implying 17% upside.

• ₹2,000 crore capex over three years expected to drive EPS growth.

• CDMO and specialty chemicals seen as key monetization avenues.

• 35% EPS CAGR projected for FY25–FY27 period.

Also Read : Govt May Hike Peak GST Rate to 60% Before Compensation Cess Ends in 2026

Robust Contract Pipeline in CDMO and Specialty Segments Supports Long-Term Visibility

One of the standout drivers of investor optimism is Navin Fluorine’s pipeline of new contracts across high-growth segments. Jefferies underlined the company’s strong visibility in the CDMO space, especially with global pharmaceutical and agrochemical majors increasingly outsourcing complex chemistry projects to Indian partners. The company’s pipeline, according to internal estimates, includes multi-year contracts expected to begin yielding revenue from FY26 onwards, with full maturity forecast by FY28. Additionally, the specialty chemical vertical—focused on fluorine-based intermediates for industrial applications—is poised to benefit from a global shift toward localized and de-risked supply chains, making Navin Fluorine a preferred partner for multinational clients seeking reliability and scalability.

Highlights

• CDMO pipeline backed by global pharma and agrochemical clients.

• Revenue from new contracts is expected from FY26 with maturity by FY28.

• Specialty segment benefits from global supply chain realignments.

• High visibility into long-term recurring revenue streams.

R32 Business Stability and Capacity Discipline Underpin Market Confidence

Beyond contract manufacturing and specialty verticals, Jefferies also remains optimistic about the R32 refrigerant gas segment—a legacy business for Navin Fluorine. Despite increasing competition and capacity additions from rival firms, the company has maintained a disciplined supply stance, which has helped sustain firm prices in the short term. The brokerage noted that Navin Fluorine’s R32 pricing power and brand strength continue to lend stability to its margin profile. This business remains a critical contributor to cash flows, allowing the company to balance newer high-growth verticals with a steady base of legacy operations. Analysts expect stable performance in this vertical to act as a financial cushion during capex recovery periods.

Highlights

• R32 refrigerant gas business continues to support margins.

• Pricing remains firm despite new industry capacities.

• Legacy segment provides financial stability amid expansion.

• Cash flow from R32 expected to aid investment recovery.

Morgan Stanley Upgrades to ‘Equal-Weight’ Citing Margin Recovery and Re-Rating Potential

Morgan Stanley also revised its view on Navin Fluorine, upgrading the stock from ‘Under-weight’ to ‘Equal-weight’ and sharply raising its price target from ₹3,242 to ₹4,160. The revised outlook is grounded in recent margin recovery, robust operational performance, and an improving order book. Analysts noted that although FY25 began on a weak note due to subdued demand and pricing pressures, the recovery in end-user segments and global macro stabilization now offer a more constructive environment. The brokerage also increased its valuation multiple on the company’s CDMO and high-performance segments from 20–22x to 25x, reflecting improved confidence in execution and earnings durability. These upgrades place Navin Fluorine among the top picks in India’s specialty chemical universe.

Highlights

• Morgan Stanley raises TP to ₹4,160, upgrades to ‘Equal-weight’.

• Higher multiples (25x) assigned to CDMO and HPP segments.

• FY25 recovery seen as turning point for sector sentiment.

• Improved order book and execution back re-rating thesis.

Strong Q4 Earnings and Market Outperformance Reinforce Growth Narrative

Navin Fluorine’s financial performance in the March 2025 quarter added further weight to the bullish sentiment. The company reported a 35.7 percent rise in consolidated net profit, reaching ₹95 crore, while revenue from operations climbed 16.45 percent year-on-year to ₹701 crore. This robust topline and bottom-line expansion comes at a time when several peer companies have struggled with demand volatility and input cost fluctuations. With a 37 percent year-to-date stock price gain, Navin Fluorine has significantly outperformed the Nifty 50 index, which is up just 5 percent in the same period. Analysts believe that the company’s consistent execution and diversification across industrial chemicals, pharmaceuticals, and refrigerants have insulated it from sectoral headwinds.

Highlights

• Q4 FY25 profit up 35.7% to ₹95 crore; revenue at ₹701 crore.

• Navin Fluorine stock up 37% YTD vs. 5% Nifty 50 rise.

• Financial strength supports positive brokerage outlooks.

• Business diversification is seen as a resilience factor.

  Know more about us-
  NiftyTrader
  GiftNifty
  BSE Option Chain
  NSE Option Chain
  IPO